Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Sharekhan and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Sharekhan

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	16 Jul 2025	Sun Pharmaceutical	Consensus Share Price Target	1711.90	1975.69	-	15.41	buy	pdf Detailed Estimates
	11 Mar 2024	Sun Pharmaceutical	Sharekhan Target	1711.90	1727.00	1584.30 (8.05%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2024	Sun Pharmaceutical	SMC online	1711.90		1407.95 (21.59%)		Results Update	pdf post cache	Broker Report Sun Pharmaceuticals Industries SMC online pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2024	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1711.90	1550.00	1407.95 (21.59%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): Strong quarter driven by specialty business BOB Capital Markets Ltd. Strong quarter with revenue/EBITDA in line and reported PAT 4% ahead of Bloomberg consensus pdf Copy Link Share on Share on Share on Share on Alert
	02 Nov 2023	Sun Pharmaceutical	Motilal Oswal Target	1711.90	1310.00	1132.85 (51.11%)	Target met	Buy	pdf post cache	Broker Report Superior execution drives broad-based revenue growth Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	02 Nov 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1711.90	1200.00	1132.85 (51.11%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): Healthy quarter; better mix supports gross margin BOB Capital Markets Ltd. Q2 revenue/PAT grew 11%/5% YoY to Rs 122bn/Rs 24bn, largely in line with consensus pdf Copy Link Share on Share on Share on Share on Alert
	02 Nov 2023	Sun Pharmaceutical	ICICI Securities Limited Target	1711.90	1210.00	1132.85 (51.11%)	Target met	Accumulate	pdf post cache	Broker Report Branded drives growth; overheads dampen margins ICICI Securities Limited Sun Pharma (Sun)’s Q2FY24 performance was lower than our expectation (though in line with Street) due to higher overheads and lower sales of gRevlimid. Traction in branded generics business across India, emerging markets and RoW coupled with specialty business in US led to 11.3% growth in revenue. pdf Copy Link Share on Share on Share on Share on Alert
	12 Sep 2023	Sun Pharmaceutical	Geojit BNP Paribas Target	1711.90	1255.00	1145.25 (49.48%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	04 Aug 2023	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1711.90	1255.00	1138.95 (50.31%)	Target met	Accumulate	pdf post cache	Broker Report US generics drives the Q1 show; launched 10 new products ICICI Securities Limited Sun Pharmaceutical’s (Sun) Q1FY24 performance was driven by better sales of generics in the US, while specialty growth took a back seat. US generics’ business ex-Taro rose 10% QoQ. Impact of lower sales of Levulan in Q1 was largely offset by higher sales of gRevlimid (estimated at USD 35-40mn) and helped Sun report an in-line result. pdf Copy Link Share on Share on Share on Share on Alert
	03 Aug 2023	Sun Pharmaceutical	Prabhudas Lilladhar Target	1711.90	1265.00	1141.00 (50.04%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMACEUTICAL I Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	03 Aug 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1711.90	1160.00	1141.00 (50.04%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): gRevlimid buoys performance; upside capped cut to HOLD BOB Capital Markets Ltd. Q1 revenue/EBITDA beat consensus by 2%/11%, but reported PAT missed estimates by 6% due to exceptional items pdf Copy Link Share on Share on Share on Share on Alert
more loading

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average share price target of 2105.29. The consensus estimate represents an upside of 22.98% from the last price of 1711.90. View 13 reports from 7 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

Sun Pharma

Sun Pharmaceuticals Industries

Sun Pharma (HOLD): Strong quarter driven by specialty business

Superior execution drives broad-based revenue growth

Sun Pharma (HOLD): Healthy quarter; better mix supports gross margin

Branded drives growth; overheads dampen margins

SUN PHARMA

US generics drives the Q1 show; launched 10 new products

SUN PHARMACEUTICAL I

Sun Pharma (HOLD): gRevlimid buoys performance; upside capped cut to HOLD

Advisor Screeners